In vitro activity of novel antifungal agents against main Aspergillus spp. tested. Epidemiological cutoff values (Ecv) recently published by CLSI were used against all species.  

Results

Activity of Isavuconazole, Itraconazole, posaconazole, and voriconazole tested against the organisms included in this study.

- Among the 639 fungal clinical isolates tested, the most active was Isavuconazole (20.0% vs 10.0%) and slightly lower when compared to Itraconazole (15.4% vs 10.0%), voriconazole (9.3% vs 10.0%), and posaconazole (9.3% vs 10.0%); 100.0% were inhibited by ≤2 µg/ml of Isavuconazole.
- For each compound, Table 1 shows the MIC90 (90.0% of isolates inhibited by ≤2 µg/ml; 11 dilutions) and MIC100 (100.0% of isolates inhibited by ≤2 µg/ml; 11 dilutions).
- In vitro activity of novel antifungal agents evaluated. Epidemiological cutoff values (Ecv) recently published by CLSI were used against all species.

Conclusions

- Isavuconazole demonstrated activity comparable to Itraconazole and voriconazole when tested against non-fermenting fungi and when read at the same test endpoint.
- Other antifungal drugs.

Acknowledgements

The authors wish to thank the SENTRY Antifungal Surveillance Program for their valuable contribution to the program.

This study was sponsored by Astellas Pharma Global Development, Inc.

References